These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1305 related items for PubMed ID: 26571482

  • 21. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM, Stall RD, Rebe K, Egan JE, De Swardt G, Struthers H, McIntyre JA.
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [Abstract] [Full Text] [Related]

  • 22. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
    Hoornenborg E, Achterbergh RC, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, van Duijnhoven YT, Sonder GJ, de Vries HJ, Prins M, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative.
    J Int AIDS Soc; 2018 Mar; 21(3):e25105. PubMed ID: 29603900
    [Abstract] [Full Text] [Related]

  • 23. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
    Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M.
    Clin Infect Dis; 2018 Jan 06; 66(2):213-219. PubMed ID: 29020194
    [Abstract] [Full Text] [Related]

  • 24. Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California.
    Myers JJ, Kang Dufour MS, Koester KA, Udoh I, Frazier R, Packard R, Kennedy K, Erguera X, Horowitz J, Grant R, Burack JH.
    J Acquir Immune Defic Syndr; 2019 Aug 01; 81(4):406-413. PubMed ID: 30973542
    [Abstract] [Full Text] [Related]

  • 25. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB.
    Lancet; 2020 Jul 25; 396(10246):239-254. PubMed ID: 32711800
    [Abstract] [Full Text] [Related]

  • 26. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM, ANRS IPERGAY study group.
    Lancet HIV; 2020 Feb 25; 7(2):e113-e120. PubMed ID: 31784343
    [Abstract] [Full Text] [Related]

  • 27. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON.
    Lancet; 2016 Jan 02; 387(10013):53-60. PubMed ID: 26364263
    [Abstract] [Full Text] [Related]

  • 28. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, Kiragu M, Reza-Paul S, Myers J, Bekker LG, Yang J, Carter C, de Boer M, Das M, Baeten JM, Celum C.
    JAMA; 2024 Mar 19; 331(11):930-937. PubMed ID: 38427359
    [Abstract] [Full Text] [Related]

  • 29. Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.
    Milam J, Jain S, Dubé MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR, CCTG Team.
    J Acquir Immune Defic Syndr; 2019 Jan 01; 80(1):e9-e13. PubMed ID: 30334877
    [Abstract] [Full Text] [Related]

  • 30. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
    Jongen VW, Hoornenborg E, van den Elshout MA, Boyd A, Zimmermann HM, Coyer L, Davidovich U, Anderson PL, de Vries HJ, Prins M, Schim van der Loeff MF, Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative.
    J Int AIDS Soc; 2021 May 01; 24(5):e25708. PubMed ID: 33973373
    [Abstract] [Full Text] [Related]

  • 31. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D, ANRS PREVENIR Study Group.
    Lancet HIV; 2022 Aug 01; 9(8):e554-e562. PubMed ID: 35772417
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Population-Level Effectiveness of HIV Pre-exposure Prophylaxis Among MSM and Transgender Persons With Bacterial Sexually Transmitted Infections.
    Pagkas-Bather J, Khosropour CM, Golden MR, Thibault C, Dombrowski JC.
    J Acquir Immune Defic Syndr; 2021 Jun 01; 87(2):769-775. PubMed ID: 33538527
    [Abstract] [Full Text] [Related]

  • 34. HIV Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex with Men in a Community-Based Sexual Health Clinic.
    Hojilla JC, Vlahov D, Crouch PC, Dawson-Rose C, Freeborn K, Carrico A.
    AIDS Behav; 2018 Apr 01; 22(4):1096-1099. PubMed ID: 29243109
    [Abstract] [Full Text] [Related]

  • 35. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
    Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG.
    PLoS One; 2019 Apr 01; 14(8):e0221281. PubMed ID: 31430318
    [Abstract] [Full Text] [Related]

  • 36. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac C, Chas J, Meyer L, Molina JM, Spire B, ANRS IPERGAY Study Group.
    AIDS Care; 2016 Apr 01; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [Abstract] [Full Text] [Related]

  • 37. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.
    J Acquir Immune Defic Syndr; 2018 Feb 01; 77(2):193-198. PubMed ID: 28991887
    [Abstract] [Full Text] [Related]

  • 38. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
    Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.
    PLoS One; 2013 Feb 01; 8(12):e81997. PubMed ID: 24367497
    [Abstract] [Full Text] [Related]

  • 39. Sexually transmitted infections incidence in young Thai men who have sex with men and transgender women using HIV pre-exposure prophylaxis.
    Songtaweesin WN, Pornpaisalsakul K, Kawichai S, Wacharachaisurapol N, Wongharn P, Yodkitudomying C, Panichnantakul P, Theerawit T, Pankam T, Puthanakit T.
    Int J STD AIDS; 2022 Apr 01; 33(5):447-455. PubMed ID: 35282719
    [Abstract] [Full Text] [Related]

  • 40. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    Kimani M, van der Elst EM, Chirro O, Wahome E, Ibrahim F, Mukuria N, de Wit TFR, Graham SM, Operario D, Sanders EJ.
    PLoS One; 2021 Apr 01; 16(1):e0244226. PubMed ID: 33465090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 66.